Compare YOUL & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YOUL | ALGS |
|---|---|---|
| Founded | 2020 | 2018 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.1M | 34.6M |
| IPO Year | 2024 | 2020 |
| Metric | YOUL | ALGS |
|---|---|---|
| Price | $0.39 | $5.43 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $52.38 |
| AVG Volume (30 Days) | ★ 55.2K | 40.3K |
| Earning Date | 12-11-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 88.30 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,186,000.00 |
| Revenue This Year | $12.81 | $1,562.10 |
| Revenue Next Year | $10.04 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.29 | $3.98 |
| 52 Week High | $2.13 | $13.69 |
| Indicator | YOUL | ALGS |
|---|---|---|
| Relative Strength Index (RSI) | 38.83 | 43.59 |
| Support Level | $0.32 | $4.93 |
| Resistance Level | $0.56 | $6.12 |
| Average True Range (ATR) | 0.07 | 0.39 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 10.83 | 29.57 |
Youlife Group Inc is a blue-collar lifetime service platform in China, dedicated to serving the needs throughout the entire life cycle of the blue-collar talent. It provides blue-collar lifetime services to students, blue-collar talent, and corporate customers. Its segments are the vocational education segment, which engages in the provision of vocational education entrusted management services, self-operated vocational school services, and Others; the HR recruitment segment engages in the provision of HR recruitment services regarding blue-collar talent to customers; the employee management segment engages in the provision of labor outsourcing services, labor dispatch services and others; and the market service segment engages in the provision of value-added services.
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.